Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24044209 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Douglas Dias E Silva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hospital Israelita Albert Einstein, Sao Paulo 05652-900, Brazil. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is considerably more frequent in squamous cell lung cancer (SqCLC) than in other subtypes of lung cancer and may be a promising target for this histology. Here, we present the course of diagnosis and treatment of a patient with advanced SqCLC, harboring not only CDKN2A mutation but also PIK3CA amplification, Tumor Mutational Burden-High (>10 mutations/megabase), and a Tumor Proportion Score of 80%. After disease progression on multiple lines of chemotherapy and immunotherapy, he responded favorably to treatment with the CDK4/6i Abemaciclib and later achieved a durable partial response to immunotherapy rechallenge with a combination of anti-PD-1 and anti-CTLA-4, nivolumab, and ipilimumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Hospital Israelita Albert Einstein, Sao Paulo 05652-900, Brazil.
- Center for Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo 05652-900, Brazil.
- Department of Oncology and Hematology, Emory University, Atlanta, GA 30322, USA.
- Department of Nuclear Medicine, Hospital Israelita Albert Einstein, Sao Paulo 05652-900, Brazil.
ORCID-Profile: Juliana Rodrigues Beal
Zitieren
APA
Dias E Silva, D., Borba, G. B., Beal, J. R., Botrus, G., Osawa, A., Araújo, S. E. A., Moura, F., Guendelmann, R. A. K., & Uson Junior, P. L. S. (2023). Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24044209
Vancouver
Dias E Silva D, Borba GB, Beal JR, Botrus G, Osawa A, Araújo SEA, et al. Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24044209
BibTeX
@article{DiasESilva2023,
author = {Dias E Silva, Douglas and Borba, Guilherme Bes and Beal, Juliana Rodrigues and Botrus, Gehan and Osawa, Akemi and Araújo, Sérgio Eduardo Alonso and Moura, Fernando and Guendelmann, Rafael Aliosha Kaliks and Uson Junior, Pedro Luiz Serrano},
title = {Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24044209}
}
EUVIMED